Licensing in the life sciences is not standard IP licensing. The regulatory environment in which life sciences companies operate (from marketing authorisations and clinical trial requirements to data exclusivity rules and post-market obligations) directly shapes the scope, structure, and risk profile of every licensing arrangement. Understanding those regulatory dynamics is essential to drafting agreements that work in practice. At the same time, life sciences licensing follows its own commercial logic: milestone-based payment structures tied to regulatory, clinical, and commercial achievements, royalty models linked to net sales or sub-licensing revenue, and deal economics that reflect the long development timelines and high failure rates inherent in the sector. Without in-depth knowledge of these customary structures and the regulatory landscape in which they operate, it is difficult to negotiate or draft a licensing agreement that properly protects your interests. We bring that knowledge to the table. We have extensive experience with licensing and IP-related contracts across the full spectrum of the life sciences, including the review and negotiation of such agreements. We help you structure your licensing arrangements so that ownership, scope of use, and commercial terms are clear and enforceable. Drawing on our understanding of patent law, trade secrets, and other forms of IP, we also advise on the broader strategic choices that underpin your contracts. We act for both licensees and licensors: whether you are a university spin-out or early-stage startup seeking to in-license foundational technology, or an established company looking to out-license your innovations to potential partners or major industry players, we ensure that the legal and commercial framework around your IP is solid.
